BIOGEN INC. Decrease in Unrecognized Tax Benefits is Reasonably Possible
BIOGEN INC. (BIIB) had Decrease in Unrecognized Tax Benefits is Reasonably Possible of $35.00 million as of 2025-09-30, per its 10-Q filed 2025-10-30.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible · last filed 2025-10-30
- 2025-09-30: Decrease in Unrecognized Tax Benefits is Reasonably Possible $35.00M.
- 2025-06-30: Decrease in Unrecognized Tax Benefits is Reasonably Possible $35.00M.
- 2025-03-31: Decrease in Unrecognized Tax Benefits is Reasonably Possible $40.00M.
- 2024-12-31: Decrease in Unrecognized Tax Benefits is Reasonably Possible $45.00M.
| Period end | Decrease in Unrecognized Tax Benefits is Reasonably Possible | Decrease in Unrecognized Tax Benefits is Reasonably Possible as first filed |
|---|---|---|
| 2025-09-30 | $35.00M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $35.00M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $40.00M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $45.00M 10-K · filed 2025-02-12 | |
| 2024-09-30 | $55.00M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $25.00M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $25.00M 10-Q · filed 2024-04-24 | |
| 2023-12-31 | $20.00M 10-K · filed 2024-02-14 | |
| 2023-09-30 | $460.00M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $470.00M 10-Q · filed 2023-07-25 | |
| 2023-03-31 | $500.00M 10-Q · filed 2023-04-25 | |
| 2022-12-31 | $500.00M 10-K · filed 2023-02-15 | |
| 2021-12-31 | $475.00M 10-K · filed 2022-02-03 | |
| 2020-12-31 | $20.00M 10-Q · filed 2021-07-22 | $25.00M 10-K · filed 2021-02-03 |
| 2019-12-31 | $75.00M 10-Q · filed 2020-10-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |